Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,647 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News


All Sessions will remain available on the Attendee Hub until October 1, 2023. Sessions are accessed through the Home page.

ZUMA-7 Data Show Axicabtagene Ciloleucel Improves OS Over Standard of Care in LBCL

Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.

Clinical Progression Outcomes ‘Inferior’ to Biochemical Progression Outcomes in Multiple Myeloma

Patients with clinical progression of relapsed multiple myeloma have “inferior” outcomes after progression compared to those with biochemical progression.

NPM1 Mutational Status has ‘Minimal Impact’ on Prognosis in Relapsed, Refractory AML

A new study suggests mutations in NPM1 have a “minimal impact” on prognosis in relapsed or refractory AML

First-in-Human Study of Revumenib Shows ‘Promising’ Activity in Acute Leukemias

Revumenib showed “promising antileukemic activity leading to deep and sustained remission” in relapsed or refractory KMT2A-rearranged or NPM1-mutant acute leukemia.

KMT2A Rearrangement in AML Linked with Early Mortality, Increased Risk of Bleeding

AML with KMT2A rearrangement is associated with a higher rate of early mortality and an increased risk of bleeding and coagulopathy compared with normal karyotype AML.

Bispecific CAR-T Targeting CD19, CD20 Is ‘Safe and Efficacious’ in Relapsed, Refractory MCL

A phase I/II trial of LV20.19, a bispecific CAR-T that targets CD19 and CD20, showed a 100% ORR and in patients with relapsed or refractory MCL

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top